CORAL GABLES, FL / ACCESSWIRE / February 27, 2019 / The success of the healthcare stock market is more nuanced than any other industry-related market because it is dependent on improving the quality of life for consumers. While industries like tech and auto develop innovative technologies for consumers, by and large, people can survive without their devices and their cars, but our health supersedes all else. The unrivaled importance of the healthcare sector comes with the expectation that companies working in the space are prepared to meet the growing demands of patients suffering from a multitude of diseases. If healthcare companies continue to provide the best quality care for their patients, this may, in turn, spark investor excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Midatech Pharma plc (MTP), Biocept Inc (BIOC), and Summit Therapeutics plc (SMMT) represent 4 healthcare stocks to keep tabs on this week.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is laser-focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to champion products and services meant to improve the quality of life for consumers.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) earlier this week announced plans to expand its development team at Cloud Practice Inc. to support the Company's focus on digitizing health care. The Company recently hired four new full-time employees, three Web Software Developers and one User Interface/User Experience (UI/UX) Designer, to support the build-out of its patient-centric platform and mobile app - a beta version of which will be available by end of Q2.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, The future of healthcare is digitally driven and this strategic investment in growing Cloud Practice's team will enable us to fast-track the build out our app - a much-needed technology innovation in healthcare. Our goal is to tackle the accessibility bottlenecks by putting the power in the hands of patients. Not only will our app enable patients' access to their health care providers, but also allow for cohesive patient care by coordinating and connecting all members of their health care team.''
Midatech Pharma plc (MTP), a research & development company focused on delivering innovative oncology and rear disease products to patients, confirmed earlier this week that further to the announcement made by the Company on 29 January 2019 and following the approval at yesterday's general meeting by shareholders of the strategic investment by China Medical Systems Holdings Limited group and A&B, the license agreement entered into by the Company and CMS is now formally in force.
Dr. Craig Cook, CEO of Midatech, said, ''we are delighted to finalize the license agreement with China Medical Systems, a leading Hong Kong-based Chinese pharmaceutical company. This is a key collaboration for Midatech that provides a strong endorsement of our technologies and pipeline whilst establishing a solid foundation for a successful and ambitious long-term partnership.''
Biocept Inc (BIOC), a leading commercial provider of liquid biopsy tests, today announced that the Company will collaborate with Providence St. Joseph Health, Southern California, and its wholly-owned affiliates Providence Saint John's Health Center and the John Wayne Cancer Institute, to conduct a study to validate the use of cerebrospinal fluid as a specimen type with Biocept's Target Selector™ liquid biopsy platform.
Following the announcement, Michael Nall, President, and CEO of Biocept, commented, ''we are very pleased to collaborate with Dr. Kesari and Providence St. Joseph Health in this study designed to further validate the clinical utility of our Target Selector™ platform using the CSF of patients with cancer among the significant advantages of our liquid biopsy technology is its versatility, which enables its application in a variety of clinical situations and for use with multiple types of biofluids.
Summit Therapeutics plc (SMMT), a leader in new mechanism antibiotic innovation, earlier this week published preclinical data on SMT-571, a new mechanism antibiotic in development for the treatment of gonorrhea, in collaboration with the Örebro University in Sweden.
Per the details of the preclinical data, studies have shown SMT-571 to have potent activity across a wide range of N. gonorrhea strains, including multi- and extensively-drug resistant ones. SMT-571 was identified using Summit's Discuva Platform, which can identify novel targets, elucidate mechanisms of action and optimize against bacterial resistance.
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
